PHILADELPHIA--(BUSINESS WIRE)--Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, announced today that Antonin (Tony) de Fougerolles had been appointed as the newest member of its Board of Directors. As the former founding CSO of Moderna, Tony is a pioneer in RNA technology with a long track record of successfully scaling biotechnology organizations from the start-up stage.
“I can’t adequately express our excitement to welcome Tony to the Chimeron Bio board,” said Afshin Safavi, Ph.D., Chairman of the Board at Chimeron. “He is widely considered a visionary in the field of RNA technology, having played a key role in developing and advancing mRNA and RNAi platforms from inception and into the clinic. In addition to his scientific expertise, he has been instrumental in scaling multiple, multi-billion-dollar companies.”
“The saRNA technology Chimeron has developed using its proprietary ChaESAR™ platform is orders of magnitude improved over linear mRNA and other saRNA approaches, and represents the next generation of RNA vaccines and therapeutics. The pipeline of drugs Chimeron is developing is exciting and can have a truly transformational impact for patients across a wide variety of diseases,” commented Tony.
Chimeron Bio’s new CEO, Kevin Heyeck, is equally excited about Tony’s board membership, noting “Tony brings an incredibly rich scientific perspective to the Chimeron board, one that will be instrumental as we continue to live out our commitment to exceptional quality and innovation. I look forward to working closely with Tony to gain his scientific insights and company-building experience to create an exceptional company that delivers important new medicines to patients.”
Chimeron Bio is actively developing next-generation saRNA-based medicines for Oncology, Infectious Diseases, and Rare Diseases. For more information about Chimeron Bio and their work, visit www.chimeron.com.
About Chimeron Bio
Chimeron Bio is a biotechnology company focused on the research of self-amplifying RNA (saRNA) towards development of novel RNA drugs and vaccines for various diseases. The company uses its proprietary ChaESAR™ platform to develop a pipeline in oncology, rare genetic disorders, and infectious diseases. It is developing two COVID-19 vaccine candidates each with its unique mechanism of action. The candidates have shown strong promise in early safety assessment and are under further development. For more information, visit www.chimeron.com.
